REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY

• US 20100158880A1
• Filed: 12/19/2009
• Published: 06/24/2010
• Est. Priority Date: 12/19/2008
• Status: Abandoned Application

• Current Assignee: Advanced Technologies and Regenerative Medicine, LLC (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Gosiewska, Anna, Seyda, Agnieszka
• Application Number:
  US12/642,773
• Publication Number:
  US 20100158880A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed.

Claims

1. A method of treating a patient having a neurological injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;

and, wherein the cells do not express CD117.

2. The method of claim 1, wherein the neurological injury is cerebral ischemia, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest, intracranial hemorrhage, intracranial lesions, whiplash or shaken infant syndrome.

3. The method of claim 1, wherein the cells are genetically engineered to produce a gene product that promotes treatment of the neurological injury.

4. The method of claim 1, wherein the cells are administered with at least one other cell type.

5. The method of claim 4, wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.

6. The method of claim 1, wherein the cells are administered at a pre-determined site in the central or peripheral nervous system of the patient.

7. The method of claim 1, wherein the umbilical cord tissue-derived cells do not express hTERT or telomerase.

8. The method of claim 1, wherein the cells are administered by injection or infusion.

15. The method of claim 1, wherein the cells require L-valine for growth and can grow in at least about 5% oxygen.

16. The method of claim 1, wherein the cells express one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

17. The method of claim 1, wherein the cells express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

18. The method of claim 1, wherein the cells does not express one or more of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

19. The method of claim 1, wherein the cells does not express any of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

21. The method of claim 1, wherein the cells express one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

22. The method of claim 1, wherein the cells express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

23. The method of claim 1, wherein the cells does not express one or more of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

24. The method of claim 1, wherein the cells does not express any of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

9. A method of stimulating regeneration capacity of a subventricular zone (SVZ) of a patient comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to increase neurogenesis, angiogenesis, or synaptogenesis, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;

and, wherein the cells do not express CD117.

10. The method of claim 9, wherein the cells are genetically engineered to produce a gene product that promotes the regeneration capacity of the subventricular zone.

11. The method of claim 9, wherein the cells are administered with at least one other cell type.

12. The method of claim 11, wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.

13. The method of claim 9, wherein the cells are administered at a pre-determined site in the central or peripheral nervous system of the patient.

14. The method of claim 9, wherein the cells are administered by injection or infusion.

20. The method of claim 9, wherein the cells require L-valine for growth and can grow in at least about 5% oxygen.

25. A pharmaceutical composition for treating a patient having a neurological injury, comprising a pharmaceutically acceptable carrier and isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;

and, wherein the cells do not express CD117.

26. The pharmaceutical composition of claim 25, wherein the cells express one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

27. The pharmaceutical composition of claim 25, wherein the cells express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

28. The pharmaceutical composition of claim 25, wherein the cells does not express one or more of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

29. The pharmaceutical composition of claim 25, wherein the cells do not express any of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

30. A kit for treating a patient having a neurological injury, the kit comprising a pharmaceutically acceptable carrier, a population of isolated umbilical cord tissue-derived cells and instructions for using the kit in a method of treating the patient, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;

and, wherein the cells do not express CD117.

31. The kit of claim 30, which further comprises a population of at least one other cell type.

32. The kit of claim 30, wherein the cells express one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

33. The kit of claim 30, wherein the cells express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

34. The kit of claim 30, wherein the cells do not express one or more of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.

35. The kit of claim 30, wherein the cells do not express any of CD31, CD34, CD45, CD141, and HLA-DR,DP,DQ.